Evidence map›Paper›PMID 42214583›Full record

ArticleAmerican journal of ophthalmology2026

Progression in Preperimetric Glaucoma Eyes With and Without Microvasculature Dropout.

Seyedeh Melika Hashemi, Takashi Nishida, Sasan Moghimi, Ghazaleh Soltani, Amelia DE Oliveira Pereira, Eleonora Micheletti, Riya Mittal, Linda M Zangwill, Robert N Weinreb

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Seyedeh Melika HashemiFrom the Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center (S.M.H., T.N., S.M., G.S., A.D.O.P., L.M.Z., R.N.W.), Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.
Takashi NishidaFrom the Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center (S.M.H., T.N., S.M., G.S., A.D.O.P., L.M.Z., R.N.W.), Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.
Sasan MoghimiFrom the Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center (S.M.H., T.N., S.M., G.S., A.D.O.P., L.M.Z., R.N.W.), Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.
Ghazaleh SoltaniFrom the Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center (S.M.H., T.N., S.M., G.S., A.D.O.P., L.M.Z., R.N.W.), Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.
Amelia DE Oliveira PereiraFrom the Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center (S.M.H., T.N., S.M., G.S., A.D.O.P., L.M.Z., R.N.W.), Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.
Eleonora MichelettiDepartment of Ophthalmology, Moorfields Eye Hospital (E.M.), London, United Kingdom.
Riya MittalDepartment of Medicine, Boston University Chobanian & Avedisian School of Medicine (R.M.), Boston, Massachusetts, USA.
Linda M ZangwillFrom the Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center (S.M.H., T.N., S.M., G.S., A.D.O.P., L.M.Z., R.N.W.), Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.
Robert N WeinrebFrom the Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center (S.M.H., T.N., S.M., G.S., A.D.O.P., L.M.Z., R.N.W.), Shiley Eye Institute, University of California San Diego, La Jolla, California, USA. Electronic address: rweinreb@ucsd.edu.

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography AngiographyR01EY029058 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEINREB, ROBERT N · 2018 to 2024
$4.2M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progressionR01EY026574 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAZIO, MASSIMO ANTONIO, GIRKIN, CHRISTOPHER ANTHONY · 2017 to 2020
$2.6M
Monitoring of Glaucoma Patients in Advanced DiseaseR01EY034148 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sasan Moghimi Araghi · 2022 to 2026
$2.5M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY026574NEI NIH HHS R01 EY027510NEI NIH HHS R01 EY029058NEI NIH HHS R01 EY034148
6 · The paper itself

Abstract

purposeTo investigate whether baseline microvasculature dropout (MvD) is associated with subsequent structural and functional changes in preperimetric glaucoma.

designSubgroup analysis of prospective cohort study data.

methodsThis study included 93 eyes from 70 participants with a glaucomatous optic disk appearance but no repeatable visual field defects, who were followed with optical coherence tomography, optical coherence tomography angiography, and visual field (VF) over a mean of 4.9 years. Circumpapillary retinal nerve fiber layer thickness and circumpapillary capillary density (cpCD) were assessed. Eyes were grouped based on the presence or absence of MvD at baseline. Mixed-effects models were used to identify factors associated with structural and functional progression.

resultsMean age was 67.7 (95% CI, 65.4-70.0) years. Among the 93 eyes, those with baseline MvD (32 eyes) showed faster loss of cpCD (-0.88 [95% CI, -1.08 to -0.67] %/year) compared to eyes without MvD (-0.23 [95% CI, -0.42 to -0.04] %/year). In multivariable models, the presence of MvD was independently associated with faster cpCD loss (-0.63 [95% CI, -0.95 to -0.32] %/year, P < .001). In contrast, it was not associated with circumpapillary retinal nerve fiber layer loss (0.03 [95% CI, -0.33 to 0.38] µm/year, P = .886). Moreover, PPG eyes that had MvD at baseline developed VF loss more frequently than those without MvD. (62.5% vs 26.2%, P < .001).

conclusionsBaseline MvD in PPG is associated with both faster vessel density loss and subsequent VF loss, and higher rates of developing glaucomatous visual field damage. Assessment of MvD can be used to estimate risk and guide the frequency of follow-up in patients with PPG.

Indexed as

GlaucomaGlaucoma, Open-AngleMicrovesselsOptic DiskRetinal VesselsVisual FieldsAgedDisease ProgressionFemaleFluorescein AngiographyFollow-Up StudiesHumansIntraocular PressureMaleMiddle AgedNerve Fibers

Identifiers

PMID42214583
PMCPMC13335619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.